Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tracey Amanda Martin has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Wen Guo Jiang

    Cardiff University

    57 shared publications
  • Robert E. Mansel

    Cardiff Univ, Sch Med, Heath Pk, Cardiff CF14 4XN, Wales

    8 shared publications
  • Gareth Watkins

    Metastasis and Angiogenesis Research Group, Department of Surgery, University of Wales College of Medicine, Heath Park, Cardiff, Wales CF14 4XN, UK

    7 shared publications
  • Wen G. Jiang

    Division of Cancer and Genetics, Cardiff China Medical Research Collaborative, University School of Medicine, Cardiff, United Kingdom

    6 shared publications
  • Jane Lane

    Cardiff University-Peking University Cancer Research Institute, Cardiff School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom

    5 shared publications
  • Fiona Ruge

    Cardiff China Medical Research Collaborative (CCMRC), School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK

    4 shared publications

Latest Publications

  • Open Access

    Beyond Barrier Function: Tight Junctions as Dynamic Signaling Hubs Orchestrating Tumor Plasticity, Microenvironment Remodeling, and Metastatic Evolution

    by Jiao Junna, Amanda Martin Tracey, Jiang Wenguo

    SCIEPublish is an international open-access journal publishing service provider run by SCIE Publishing Limited, dedicated to supporting and inspiring scientists or institutions/societies who aspire to publish high-quality journals.

  • Open Access

    Tight junctional protein family, Claudins in cancer and cancer metastasis

    by Wenxiao Ji, Xinguo Zhuang, Wen G. Jiang, Tracey A. Martin

    Claudin (CLDN) family proteins are key components of tight junctions in epithelial and endothelial cells, crucial for controlling paracellular permeability and cell-cell adhesion. Aberrant CLDNS expression is frequently observed in cancers and has been linked to tumor progression, invasion, and metastasis. Recent years have seen a rapid advance in exploring the role played by this protein family in cancer and cancer metastasis, and even chemotherapy response. This article provides a comprehensive overview of the roles of CLDNs in solid tumors, highlighting how specific CLDN members function as oncogenic drivers or tumor suppressors in different cancer types. We also discuss the potential of CLDNs as biomarkers for prognosis and therapeutic targets (e.g. CLDN18.2-targeted immunotherapy). The inclusion of updated literature (particularly post-2020) and bioinformatic analyses (TCGA/GEPIA) reveal emerging trends. Finally, we summarize common patterns of CLDN dysregulation across cancers and outline future research directions, including pan-cancer CLDN analyses and translational strategies.


  • Open Access

    Knockdown of Claudin-8 (CLDN8) Indicates a Link Between Breast Cancer Cell Sensitivity to Chemotherapeutics and Reveals a Potential Use of CLDN8 as a Molecular Diagnostic and Target for Therapy

    by Wenxiao Ji, Yufei Lou, Wen G. Jiang, Fiona Ruge, Tracey A. Martin

    Breast cancer is a heterogeneous disease, and treatment resistance remains a critical challenge. Claudin-8 (CLDN8), a tight junction protein, has emerged as a potential indicator of therapeutic response and prognosis in breast cancer patients. In this study, we evaluated CLDN8 as a predictive biomarker and a potential therapeutic target. We analyzed CLDN8 gene expression in breast cancer patient cohorts to assess its association with clinical outcomes and response to therapy. We also established breast cancer cell models with altered CLDN8 expression to examine its effects on cell behavior and drug sensitivity. High CLDN8 expression was significantly associated with improved disease-free survival, particularly in estrogen receptor-negative patients (p = 0.007), suggesting a favorable prognostic role. Notably, tumors with elevated CLDN8 showed better outcomes in patients treated with surgery alone or endocrine therapy, whereas in those receiving chemotherapy (including neoadjuvant) or anti-HER2 therapy, high CLDN8 levels were paradoxically linked to poorer survival and therapy resistance. In vitro, CLDN8 knockdown reduced sensitivity to endocrine treatments, HER2-targeted agents, and chemotherapeutic drugs, mirroring clinical patterns. In conclusion, our findings identify CLDN8 as an important prognostic factor in breast cancer and as a novel predictor of treatment response. These results underscore the potential utility of CLDN8 status in guiding personalized therapy and highlight CLDN8 as a candidate target for overcoming treatment resistance in breast cancer.


  • Open Access

    The WASP/WAVE Protein Family in Breast Cancer and Their Role in the Metastatic Cascade

    by Rhiannon Yannan Yu, Wen G. Jiang, Tracey A. Martin

    The Wiskott–Aldrich syndrome protein (WASP) and the WASP family verprolin-homologous protein (WAVE) family are essential molecules that connect GTPases to the actin cytoskeleton, thereby controlling actin polymerisation through the actin-related protein 2/3 complex. This control is crucial for forming actin-based membrane protrusions necessary for cell migration and invasion. The elevated expression of WASP/WAVE proteins in invasive breast cancer cells highlights their significant role in promoting cell motility and invasion. This review summarises the discovery, structural properties, and activation mechanisms of WASP/WAVE proteins, focuses on the contribution of the WASP/WAVE family to breast cancer invasion and migration, particularly synthesises the results of nearly a decade of research in this field since 2015. By exploring promising therapeutic strategies for breast cancer, including small molecule inhibitors and biological agents, this review stresses the potential for developing anticancer drugs that target the WASP/WAVE family and associated pathways, intending to improve the prognosis for patients with metastatic breast cancer.


  • Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway

    by Kaitao Zhu, Shiwei Li, Hongru Yao, Jilong Hei, WenGuo Jiang, Tracey Martin, Shanyi Zhang

    Purpose Breast cancer brain metastasis (BCBM) is a deadly clinical problem, and the exact underlying mechanisms remain elusive. Junctional adhesion molecule (JAM), a tight junction protein, is a key negative regulator of cancer cell invasion and metastasis. Methods Junction adhesion molecule 3 (JAM3) expression in breast cancer was analyzed using bioinformatics methods and confirmed by PCR, western blotting, and immunofluorescence (IF) in cell lines. The effects of exogenous expression of JAM3 using lentiviral vectors on invasion, adhesion, and apoptosis were verified using transwell assays and flow cytometry. Differentially expressed genes (DEGs) were detected by RNA sequencing and verified by q‒PCR and Western blotting. The effect of JAM3 silencing using siRNA was assessed by an adhesion assay. Kaplan‒Meier analysis was applied to calculate the impact of JAM3 expression and classic clinicopathologic characteristics on survival. Results Bioinformatics analysis revealed that JAM3 expression was reduced in BCBM. Exogenous expression of JAM3 minimizes the ability of breast cancer cells to invade and adhere and promotes their apoptosis. Silencing JAM3 results in morphology changes and the recovery of invasion and adhesion to ECMs, and the TGF-β/Smad signaling pathway may be involved. JAM3 predicts less metastasis and good survival in patients with BCBM. Statistical analysis of BCBM samples detected by immunohistochemistry (IHC) and the associated clinicopathological characteristics revealed that low levels of JAM3 expression and high levels of TNF-β1 are linked to the clinical progression of both primary and metastatic breast tumors. Kaplan–Meier analysis revealed that a high expression level of JAM3 was associated with longer survival. Conclusion JAM3 can serve as a key negative regulator of breast cancer cell invasion, apoptosis, and brain metastasis, possibly through the TGF/Smad signaling pathway. JAM3 is anticipated to be a promising biomarker for the diagnosis and prognosis of breast cancer.


  • Open Access

    Exploring the Role of N-WASP in Breast Cancer Metastasis through Mass Spectrometry and Potential Signalling Pathway Analysis

    by Rhiannon Yannan Yu, Wenguo Jiang, Tracey Martin

    Background: Neural Wiskott–Aldrich Syndrome Protein (N-WASP) is a key regulator of the actin cytoskeleton and is implicated in various cellular processes, including cell motility and invasion. In cancer biology, the role of N-WASP in cell motility and metastasis is of particular interest, yet its specific functions in breast cancer remain to be fully understood. Method: To investigate the impact of N-WASP on breast cancer cell behaviour, we employed siRNA to knock down N-WASP expression in the MDA-MB-231 breast cancer cell line. After the knockdown, proteomic changes in the cells were analysed using mass spectrometry. Notable alterations in the genes present in both total and phosphorylated proteins were further analysed. Results: The proteomic data analysis ranked 50 genes that exhibited the most up-regulation and down-regulation in total and phosphorylated proteins. These 200 genes were further examined using the REACTOME database to identify affected signalling pathways. Knockdown of N-WASP led to significant changes in the RHOD, RHOF, and RHOG GTPase cycles (p = 0.015, p = 0.01, and p = 0.027), pathways closely associated with cell motility and actin cytoskeleton organisation. These cycles are crucial in modulating cellular dynamics, impacting a range of processes from immune response to neuronal development, wound healing, and, particularly, cancer metastasis. Furthermore, the findings highlighted the role of non-integrin membrane–ECM interactions in cell motility and cytoskeleton dynamics (p = 0.021). The altered protein expression patterns suggest a link between N-WASP, non-integrin membrane–ECM interactions, and the cytoskeletal changes essential for cell migration and invasion—key factors in cancer metastasis. Conclusions: Our findings reinforce the critical role of N-WASP in regulating the cytoskeleton and influencing cell motility, invasion, and metastasis in breast cancer. This study not only provides deeper insights into the molecular mechanism of breast cancer progression but also highlights N-WASP as a potential therapeutic target for intervention strategies in breast cancer treatment.

  • Open Access

    Cellular Impacts of Striatins and the STRIPAK Complex and Their Roles in the Development and Metastasis in Clinical Cancers (Review)

    by Amber Xinyu Li, Tracey A. Martin, Jane Lane, Wen G. Jiang

    Striatins (STRNs) are generally considered to be cytoplasmic proteins, with lower expression observed in the nucleus and at cell–cell contact regions. Together with protein phosphatase 2A (PP2A), STRNs form the core region of striatin-interacting phosphatase and kinase (STRIPAK) complexes through the coiled-coil region of STRN proteins, which is crucial for substrate recruitment. Over the past two decades, there has been an increasing amount of research into the biological and cellular functions of STRIPAK members. STRNs and the constituent members of the STRIPAK complex have been found to regulate several cellular functions, such as cell cycle control, cell growth, and motility. Dysregulation of these cellular events is associated with cancer development. Importantly, their roles in cancer cells and clinical cancers are becoming recognised, with several STRIPAK components found to have elevated expression in cancerous tissues compared to healthy tissues. These molecules exhibit significant diagnostic and prognostic value across different cancer types and in metastatic progression. The present review comprehensively summarises and discusses the current knowledge of STRNs and core STRIPAK members, in cancer malignancy, from both cellular and clinical perspectives.


  • Open Access

    Expression of Claudin-9 (CLDN9) in Breast Cancer, the Clinical Significance in Connection with Its Subcoat Anchorage Proteins ZO-1 and ZO-3 and Impact on Drug Resistance

    by Xinguo Zhuang, Tracey A. Martin, Fiona Ruge, Jianyuan (Jimmy) Zeng, Xinyu (Amber) Li, Elyas Khan, Qingping Dou, Eleri Davies, Wen G. Jiang

    (1) Introduction: Claudin-9 (CLDN9) is a member of the claudin protein family, a critical transmembrane protein family for tight junctions that are implemented in the progression of numerous cancer types. The present study investigated the role that CLDN9, along with the subcoat proteins, Zonula Occludens (ZOs), plays in clinical breast cancer and subsequent impact on drug response of patients. (2) Methods: CLDN9 protein and CLDN9 transcript were determined and correlated with clinical and pathological indicators, together with the status of hormonal receptors. The levels of CLDN9 transcript were also assessed against the therapeutic responses of the patients to chemotherapies by using a dataset from the TCGA database. Breast cancer cell models, representing different molecular subtypes of breast cancer, with differential expression of CLDN9 were created and used to assess the biological impact and response to chemotherapeutic drugs. (3) Results: Breast cancer tissues expressed significantly higher levels of the CLDN9, with the high levels being associated with shorter survival. CLDN9 was significantly correlated with its anchorage proteins ZO-1 and ZO-3. Integrated expression of CLDN9, ZO-1 and ZO-3 formed a signature that was significantly linked to overall survival (OS) (p = 0.013) and relapse-free survival (RFS) (p = 0.024) in an independent matter. CLDN9 transcript was significantly higher in patients who were resistant to chemotherapies (p < 0.000001). CLDN9 connection to chemoresistance was particularly prominent in patients of ER-positive (ER(+)), Her-2-negative((Her-2(−)), ER(+)/Her-2(−) and triple-negative breast cancers (TNBCs), but not in patients with HER-2-positive tumors. In Her-2-negative MCF7 and MDA-MB-231 cancer cells, loss of CLDN9 significantly increased sensitivity to several chemotherapeutic drugs including paclitaxel, gemcitabine and methotrexate, which was not seen in Her-2(+) SKBR3 cells. However, suppressing Her-2 using neratinib, a permanent Her-2 inhibitor, sensitized cellular response to these chemodrugs in cells with CLDN9 knockdown. (4) Conclusions: CLDN9 is an important prognostic indicator for patients with breast cancer and also a pivotal factor in assessing patient responses to chemotherapies. Her-2 is a negating factor for the treatment response prediction value by CLDN9 and negating Her-2 and CLDN9 may enhance breast cancer cellular response to chemotherapeutic drugs.


  • Open Access

    Claudin-10 in the Blood Brain Barrier Function of Cerebral Endothelial Cells and Transendothelial Invasion of Breast Cancer Cells

    by Xinguo Zhuang, Wenxiao Ji, Ziqian Fang, Yiming Yang, Fiona Ruge, Q. Ping Dou, Xun Li, Bing Xu, Wen G. Jiang, Tracey A. Martin

    Background/Aim: Claudin-10 (CLDN10) is a membrane integral protein. It is one of the widely expressed tight junctional claudins with functions not well defined. In the present study, the expression profile and its role in cerebral endothelial cells and in the interaction between breast cancer and endothelial cells were investigated. Materials and Methods: CLDN10 expression was examined in a wide range of cell types. Brain endothelial cell models with or without CLDN10 expression were generated using the hCMEC/D3 cell line and used to test the barrier and permeability functions. Transendothelial drug delivery and invasion were also evaluated. Results: hCMEC/D3 cells express high levels of CLDN10, compared with peripheral endothelial cells, mesothelial cells, fibroblasts, and breast cancer cells, which were either negative or expressed low levels of CLDN10. Knockdown of CLDN10 in hCMEC/D3 cells resulted in impaired tight junctions as seen by reduced transendothelial electric resistance and paracellular permeability. It also accelerated invasion of breast cancer cells through the endothelial cell layer. CLDN10 knockdown in hCMEC/D3 cells led to an increase in transendothelial chemodrug delivery. Furthermore, the SRC kinase inhibitor (AZM475271) was able to decrease the impedance and increase the paracellular permeability in cerebral endothelial cells. Conclusion: Cerebral endothelial cells express high levels of CLDN10, a protein regulating barrier function and thereby drug permeability and cancer invasiveness in brain endothelial cells, suggesting that it is a novel therapeutic target for the treatment of brain metastasis-related diseases.


  • Open Access

    nWASP Inhibition Increases Wound Healing via TrKb/PLCγ Signalling

    by Bethan A. Frugtniet, Fiona Ruge, Andrew J. Sanders, Sioned Owen, Keith G. Harding, Wen G. Jiang, Tracey A. Martin

    (1) Background: Chronic wounds represent a major burden to patients and healthcare systems and identifying new therapeutic targets to encourage wound healing is a significant challenge. This study evaluated nWASP as a new therapeutic target in human wound healing and determined how this can be regulated. (2) Methods: Clinical cohorts from patients with chronic wounds were tested for the expression of nWASP and cell models were employed to evaluate the influence of nWASP on cellular functions that are key to the healing process following knockdown and/or the use of nWASP-specific inhibitors. (3) Results: nWASP was significantly elevated at transcript levels in human non-healing chronic wounds versus healing tissues. nWASP inhibitors, wiskostatin and 187-1, along with the knockdown of nWASP, modified both HaCaT and HECV cell behaviour. We then identified two signalling pathways affected by nWASP inhibition: TrkB signalling and downstream PLCγ1 phosphorylation were impaired by nWASP inhibition in HaCaT cells. The healing of wounds in a diabetic murine model was significantly improved with an nWASP inhibitor treatment. (4) Conclusions: This study showed that nWASP activity was related to the non-healing behaviour of chronic wounds and together with the findings in the in vivo models, it strongly suggested nWASP as a therapeutic target in non-healing wounds that are regulated via TrkB and PLCγ1 signalling.